Home>Topics>Stocks>Affymax

Affymax AFFY

  1. All
  2. Commentary
  3. Stock Reports
  4. ETF Reports
  5. Headlines
    1. Midday top 10 gainers: [[CERE]] +73%. [[CTB]] +41%. [[SGOC]] +28%. [[ULTA]] +17%. [[GPRC]] +14%. [[SE]] +10%. [[UQM]] +9%. [[ AFFY ]] +9%. [[AMED]] +9%. [[HMA]] +9%. Midday top 10 Losers: [[IQNT]] ...

      Headlines

      Wed, 12 Jun 2013

      Midday top 10 gainers: CERE +73% . CTB +41% . SGOC +28% . ULTA +17% . GPRC +14% . SE +10% . UQM +9% . AFFY +9% . AMED +9% . HMA +9% . Midday top 10 Losers: IQNT -17% . KNDI -17% . CLSN -14% . TELK -12% . RLOG -12

    2. Midday top 10 gainers: [[SGOC]] +25%. [[ACAD]] +17%. [[STEL]] +17%. [[MPAA]] +14%. [[TRMD]] +9%. [[OVAS]] +13%. [[CLIR]] +13%. [[TPLM]] +12%. [[RVLT]] +13%. [[KNDI]] +12%. Midday top 10 Losers: ...

      Headlines

      Mon, 10 Jun 2013

      13% . CLIR +13% . TPLM +12% . RVLT +13% . KNDI +12% . Midday top 10 Losers: DVAX -35% . OSH -18% . ECTE -16% . AFFY -14% . AEPI -14% . OMX -12% . SHI -12% . PLM -11% . GNRC -11% . CBAK -11% . Post your comment!

    3. Midday top 10 gainers: [[OSH]] +23%. [[WSBF]] +19%. [[OPTT]] +17%. [[CSFS]] +14%. [[BDBD]] +13%. [[JKS]] +11%. [[ROSG]] +11%. [[THO]] +10%. [[ECTY]] +10%. [[KFS]] +9%. Midday top 10 Losers: [[FSGI]] ...

      Headlines

      Fri, 7 Jun 2013

      JKS +11% . ROSG +11% . THO +10% . ECTY +10% . KFS +9% . Midday top 10 Losers: FSGI -56% . TIVO -17% . USM -17% . IRM -16% . ZQK -12% . JRCC -11% . LQDT -11% . AFFY -10% . CBPO -10% . TRUE -8% . Post your comment!

    4. Affymax Drops On Nasdaq Delisting And Criticism

      Headlines

      Tue, 4 Jun 2013

      By Brian L. Wilson : In February 2013, Affymax (NASDAQ: AFFY ) made headlines after a nationwide voluntary recall ..... 7% at the time of writing. Things worsened for Affymax shareholders when the company announced a month later

    5. Shares of Affymax ([[ AFFY ]] +31.5%) soar today on the back of what appears to be a massive short squeeze. The most recent data on the stock has short interest rising 43% from the start to middle of ...

      Headlines

      Fri, 31 May 2013

      Shares of Affymax ( AFFY +31.5% ) soar today on the back of what appears to be a massive short squeeze . The most recent data on the stock has short

    6. Premarket gainers: [[OVTI]] +21%. [[NBG]] +19%. [[ AFFY ]] +8%. [[CLSN]] +8%. [[KKD]] +7%. [[ETRM]] +6%. [[LEDS]] +6%. [[GES]] +5%. Losers: [[PANW]] -13%. [[PLM]] -12%. [[MHGC]] -7%. [[NMR]] -6%.

      Headlines

      Fri, 31 May 2013

      Premarket gainers: OVTI +21% . NBG +19% . AFFY +8% . CLSN +8% . KKD +7% . ETRM +6% . LEDS +6% . GES +5% . Losers: PANW -13% . PLM -12% . MHGC -7% . NMR -6% . Post your comment!

    7. Keryx: Attractive In Front Of Catalyst-Rich Second Half

      Headlines

      Thu, 30 May 2013

      By PropThink : By Jake King Shares of Keryx Biopharmaceuticals ( KERX ) continue to trade within a tight range, but with several catalyzing events approaching, we believe the stock is ready to break out. In particular, clinical evidence for a second, larger indication for Keryx's late-stage ...

    8. Affymax Is Still Alive

      Headlines

      Tue, 28 May 2013

      possible reversal, you will see that biotech company Affymax ( AFFY ) stock did in fact bounce in share price recently ..... traders like me may want to continue to hold. In short, Affymax is still alive. Some speculative traders who entered

    9. Premarket gainers: [[CHCI]] +41%. [[DVR]] +25%. [[CLNT]] +14%. [[VIPS]] +13%. [[EJ]] +11%. [[ AFFY ]] +9%. [[CHLN]] +9%. [[SPWR]] +8%. [[AVEO]] +5%. Losers: [[XONE]] -10%. [[RMTI]] -8%. [[WMC]] -5%.

      Headlines

      Wed, 15 May 2013

      Premarket gainers: CHCI +41% . DVR +25% . CLNT +14% . VIPS +13% . EJ +11% . AFFY +9% . CHLN +9% . SPWR +8% . AVEO +5% . Losers: XONE -10% . RMTI -8% . WMC -5% . 2 comments!

    10. New Morningstar Analyst Report - Amgen

      Stock Reports

      Mon, 13 May 2013

      Epogen and Aranesp to see stronger sales in the near term, particularly over the next two years, following the withdrawal of Affymax 's Omontys from the market. Sales growth from Prolia/Xgeva, Nplate, and Amgen's late-stage pipeline should largely

    « Prev12345Next »
    Content Partners